The drug failed to hit its Phase III targets.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Chronic disease patients seek online support and information, and show little love for branded websites.
Forest's cost-savings initiative is aimed at reducing operating expenses by $500 million, while Eisai said it's cutting 130 positions in the US and Europe.
Spectrum DNA says its genetic services are at the ready, even if 23andMe's are not.
The leukemia drug is staying on the market, but for a more restricted patient population.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
Actavis shrinks its staff by 30%, and Bayer reduces its California footprint.
The agency's bad-ad warning letter calls the new violations "particularly troubling."
The patient population is small, at around 3,000, but the expected price tag is $330,000 a year.